Overview

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Status:
Withdrawn

Trial end date:
2018-07-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach target blood pressure following 4 weeks of treatment with amlodipine monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Amlodipine
Candesartan
Candesartan cilexetil